From discovery to translation: ARMI spinout Myostellar targets muscle regeneration with support from Monash Ventures Pre-Seed Fund

A major regenerative medicine discovery from Monash University’s Australian Regenerative Medicine Institute (ARMI) has progressed into early-stage commercialisation, with the Monash spinout Myostellar among the inaugural cohort of spinouts to receive support from the newly launched Monash Ventures Pre-Seed Fund.

Founded by Professors Peter Currie and Mikaël Martino, two internationally recognised leaders in tissue regeneration, Myostellar is developing a new class of therapies designed to stimulate skeletal muscle regeneration. The company aims to address an urgent unmet need for people living with conditions such as muscular dystrophies, for which there are currently no approved treatments that restore lost muscle function.

“Our team has spent years building the foundational science behind this approach,” said Professor Martino. “With this funding in place, we can now continue focusing on translating our discoveries into therapies that can truly improve lives, starting with muscular dystrophy, but with broader applications across muscle diseases and muscle wasting conditions.”

The company builds on discoveries made at ARMI and published in Nature in 2021, where the team demonstrated the regenerative potential of a novel molecule in mouse models. Their approach harnesses the body’s own repair mechanisms, modulating immune and fibrotic responses to support healthy muscle regrowth.

“When we found that our molecule could regenerate muscle to a remarkable extent in preclinical models, we knew we were onto something big,” said Professor Martino. “Now the goal is to develop it into a therapy that can make a real difference in patients’ lives.”

As part of the inaugural round of investments from the Monash Ventures Pre-Seed Fund, Myostellar has joined a new generation of research-led companies advancing technologies with commercial and societal impact. The fund, managed in partnership with Breakthrough Victoria, forms a key pillar of Monash’s innovation strategy, helping spinouts accelerate translation and attract further investment.

“The funding from the Monash Ventures Pre-Seed Fund will unlock for us a better understanding of the mechanism of action of the drug but also a real knuckle-down approach to delivering the therapy,” said Currie.

“We are very confident because we have a molecule that works and now we really need to translate that into a therapeutic that can be used by patients,” added Martino.

The team anticipates that it will take approximately two years to reach the stage where the therapy is ready for clinical application.

Alongside Professors Currie and Martino, the Myostellar team includes Chief Operating Officer Dr Bo Yun, who brings commercial and operational leadership to the company’s next phase.

The company’s progress has also been supported by CUREator, the national biomedical incubator managed by Brandon BioCatalyst, which played a key role in helping Myostellar move from discovery to early-stage development.

“Myostellar wouldn’t exist without the CUREator and the Precinct Fund,” said Currie. “We acknowledge the critical role that the government funding has played in this.”

Myostellar is one of several research-led companies to emerge from ARMI, reflecting the institute’s ongoing commitment to translating regenerative biology into real-world therapies.

Watch the full story behind Myostellar and the Monash Ventures Pre-Seed Fund: https://www.youtube.com/watch?v=RBDByJDXn0w

Media contact:
Dr Marguerite Evans-Galea
Deputy Director, Strategy & Planning, ARMI
armi@monash.edu
+61 (0) 488438001